Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cymbalta Duloxetine hydrochloride Pain, Neuropathic, Diabetic List with clinical criteria and/or conditions Complete
Cymbalta Duloxetine hydrochloride Depressive, Major Disorder (MDD) Do not list Complete
Cyramza Ramucirumab Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Cyramza Ramucirumab Cancelled
Cystadrops cysteamine Corneal cystine crystal deposits Reimburse with clinical criteria and/or conditions Complete
Daklinza Daclatasvir Hepatitis C, Chronic List with clinical criteria and/or conditions Complete
Daklinza daclatasvir Hepatitis C, Chronic Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab Rd for MM Reimburse with clinical criteria and/or conditions Complete
Darzalex daratumumab Light chain (AL) amyloidosis Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab Multiple Myeloma (second-line) Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab Multiple Myeloma Do not reimburse Complete
Darzalex Daratumumab BMP for Multiple Myeloma (newly diagnosed) Reimburse with clinical criteria and/or conditions Complete
Darzalex daratumumab Multiple myeloma, eligible for autologous stem cell transplant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Daurismo Glasdegib Acute Myeloid Leukemia (AML) Do not reimburse Complete
Daxas Roflumilast Chronic obstructive pulmonary disease Do not list Complete
Dayvigo lemborexant Insomnia Do not reimburse Complete
Delstrigo doravirine lamuvidine tenofovir disoproxil fumarate HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Demylocan decitabine Myelodysplastic Syndromes Unable to recommend reimbursement Not filed
Denavir Penciclovir Herpes labialis (cold sores) Do not list Complete
Descovy Emtricitabine /tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Diacomit Stiripentol Dravet Syndrome List with criteria/condition Complete
Dificid Fidaxomicin Clostridium difficile infection Do not list at the submitted price Complete
Dificid fidaxomicin Clostridium difficile infection Active
Dojolvi triheptanoin Long-chain fatty acid oxidation disorders Reimburse with clinical criteria and/or conditions Complete
Doptelet avatrombopag Chronic immune thrombocytopenia (ITP) Do not reimburse Active